Recombinant Human VEGF-C Protein, CF | R&D Systems 9199-VC-025/CF product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human VEGF-C Protein, CF

catalog :

9199-VC-025/CF

quantity :

25 ug

price :

400 USD

citations: 9

Reference
Islam R, Mishra J, Polavaram N, Bhattacharya S, Hong Z, Bodas S, et al. Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance. Cell Rep. 2022;40:111097 pubmed publisher
Morfoisse F, De Toni F, Nigri J, Hosseini M, Zamora A, Tatin F, et al. Coordinating Effect of VEGFC and Oleic Acid Participates to Tumor Lymphangiogenesis. Cancers (Basel). 2021;13: pubmed publisher
Geng X, Yanagida K, Akwii R, Choi D, Chen L, Ho Y, et al. S1PR1 regulates the quiescence of lymphatic vessels by inhibiting laminar shear stress-dependent VEGF-C signaling. JCI Insight. 2020;5: pubmed publisher
Chung T, Kim E, Choi H, Han C, Jang S, Kim K, et al. 6'-Sialylgalactose inhibits vascular endothelial growth factor receptor 2-mediated angiogenesis. Exp Mol Med. 2019;51:1-13 pubmed publisher
López Bellido R, Puig S, Huang P, Tsai C, Turner H, Galko M, et al. Growth factor signaling regulates mechanical nociception in flies and vertebrates. J Neurosci. 2019;: pubmed publisher
Frye M, Taddei A, Dierkes C, Martínez Corral I, Fielden M, Ortsäter H, et al. Matrix stiffness controls lymphatic vessel formation through regulation of a GATA2-dependent transcriptional program. Nat Commun. 2018;9:1511 pubmed publisher
Lin Y, Ohbayashi N, Hongu T, Katagiri N, Funakoshi Y, Lee H, et al. Arf6 in lymphatic endothelial cells regulates lymphangiogenesis by controlling directional cell migration. Sci Rep. 2017;7:11431 pubmed publisher
Campbell K, Hadley D, Kukis D, Silva E. Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications. PLoS ONE. 2017;12:e0181484 pubmed publisher
Yu S, Lv H, Zhang H, Jiang Y, Hong Y, Xia R, et al. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway. Biochem Biophys Res Commun. 2017;485:432-439 pubmed publisher

product information

master code :

9199-VC/CF

SKU :

9199-VC-025/CF

product name :

Recombinant Human VEGF-C Protein, CF

unit size :

25 ug

description :

The Recombinant Human VEGF-C Protein, CF from R&D Systems is derived from CHO. The Recombinant Human VEGF-C Protein, CF has been validated for the following applications: Bioactivity.

target :

VEGF-C

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in HCl.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.

species :

Human

observed molecular weight :

14-22 kDa, reducing conditions

theoretical molecular weight :

13 kDa

details of functionality :

Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al . (1999) Proc. Natl. Acad. Sci. USA 96 :9671. The ED50 for this effect is 1.5-9 ng/mL.

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

top caption :

Recombinant Human VEGF-C Protein Bioactivity

accessionNumbers :

P49767

applications :

Bioactivity

source long :

Chinese Hamster Ovary cell line, CHO-derived human VEGF-C protein Ala112-Arg227

source short :

CHO

USD :

400 USD

alt names :

Flt4 ligand, Flt4-L, vascular endothelial growth factor C, Vascular endothelial growth factor-related protein, VEGFC, VEGF-C, VRPFLT4 ligand DHM

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.